These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3600587)

  • 1. [DU-PAN-2 antigen in the serum of patients with tumors of the pancreas or biliary tract].
    Ohshio G; Hamashima Y; Manabe T; Miyashita T; Suzuki T; Tobe T
    Nihon Geka Gakkai Zasshi; 1987 Mar; 88(3):359. PubMed ID: 3600587
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical significance of DU-PAN-2 analysis as a tumor marker].
    Sawabu N; Satomura Y
    Nihon Rinsho; 1990 Feb; 48 Suppl():1003-7. PubMed ID: 2162408
    [No Abstract]   [Full Text] [Related]  

  • 3. [Detection of DU-PAN-2 antigen (pancreatic cancer-associated antigen) in sera of patients with cancer of the digestive tract].
    Takami H; Furuuchi T; Ogata Y; Abe O
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3207-14. PubMed ID: 3777958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of pancreatic oncofetal antigen, pancreatic cancer associated antigen assay as tumor markers].
    Shimano T; Morimoto H; Saito M; Mori T
    Nihon Rinsho; 1990 Feb; 48 Suppl():917-9. PubMed ID: 2192174
    [No Abstract]   [Full Text] [Related]  

  • 7. [CA 19-9, a new tumor marker].
    Akai S
    Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tumor markers in hepatoma, gallbladder-biliary tract and pancreas cancer].
    Nakahara M; Fujisawa K
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3010-9. PubMed ID: 2445292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of serum DU-PAN-2 surveyed by solid-phase sandwich EIA for DU-PAN-2].
    Ishii M; Urabe T; Seino Y
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1860-5. PubMed ID: 3296960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
    Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
    Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
    Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
    J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker.
    DelVillano BC; Zurawski VR
    Lab Res Methods Biol Med; 1983; 8():269-82. PubMed ID: 6196588
    [No Abstract]   [Full Text] [Related]  

  • 13. [Basic and clinical studies on SPan-1 RIABEAD kit: usefulness in patients with pancreatic and biliary tract cancer].
    Watanabe Y; Endo K; Nakajima K; Hattori N; Sakahara H; Saga T; Nakai T; Hosono M; Yao ZS; Baba N
    Kaku Igaku; 1989 Dec; 26(12):1559-65. PubMed ID: 2622087
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical significance of YH-206 assay analysis as a tumor marker].
    Yachi A; Hinoda Y; Imai K; Endo T
    Nihon Rinsho; 1990 Feb; 48 Suppl():1068-70. PubMed ID: 2192107
    [No Abstract]   [Full Text] [Related]  

  • 15. Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinomas.
    Borowitz MJ; Tuck FL; Sindelar WF; Fernsten PD; Metzgar RS
    J Natl Cancer Inst; 1984 May; 72(5):999-1005. PubMed ID: 6371347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of serum DU-PAN-2 by enzyme immunoassay in patients with various digestive cancers].
    Takemori Y; Sawabu N; Satomura Y; Ohta H; Watanabe H; Okai T; Mai M; Hattori N; Akiyama T; Hashimoto T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):119-26. PubMed ID: 3541791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ultrasonic diagnosis of neoplasms of liver, biliary tract and pancreas].
    Kitamura T
    Nihon Rinsho; 1982; 40(1):71-8. PubMed ID: 7087207
    [No Abstract]   [Full Text] [Related]  

  • 18. [Occurrence of pancreatic tumor markers and diagnosis of small pancreatic tumors. 5). DU-PAN-2].
    Sawabu N; Satomura Y; Takemori Y
    Nihon Rinsho; 1986 Aug; 44(8):1830-3. PubMed ID: 3537374
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pancreatic and biliary tract cancers].
    Sawada T; Yamada N; Hirakawa K
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):865-71. PubMed ID: 11432359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunological markers in the detection of neoplasms of the liver, biliary tract and pancreas].
    Matsuno S; Kobari M; Kodera T; Sato T
    Nihon Rinsho; 1982; 40(1):51-7. PubMed ID: 6177882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.